Law360, New York (October 30, 2015, 8:35 PM EDT) -- Pharmaceutical giant Pfizer's latest cross-border pursuit is already reigniting the discussion of so-called inversions roughly a year after rules surrounding the tax-motivated deal structure were tightened, posing a potential threat to a deal that has yet to even materialize.
Pfizer Inc. and Irish drugmaker Allergan PLC confirmed Thursday that they were mulling a potential deal, though both companies emphasized that there was no guarantee a deal would be reached. Although neither shed any light on how a transaction would be structured, an inversion would fall in line with what several other U.S. drugmakers — including Allergan — have done by redomiciling in...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!